The European Medicines Agency has recommended expanding the use of "Imvanex" vaccine against monkeypox.

APA reports that this was stated in the information released by the European Medicines Agency.

This vaccine has been approved for the prevention of smallpox in the European Union since 2013.

The agency said that "Imvanex" will be effective in preventing monkeypox in humans.

According to experts, side effects of the drug are mild to moderate, and the benefits of using it outweigh the risks.

Based on these recommendations, necessary changes will be made to the instructions for the use of the drug in the near future.